Table 1.

Baseline characteristics

Study Population Baseline CharacteristicsControl, N=40Intervention, N=40
Age, yr, mean (SD)56.7 (15.3)55.2 (12.6)
Men, N (%)24 (60)19 (48)
Women, N (%)16 (40)21 (52)
Race, N (%)
 White31 (78)29 (73)
 Aboriginal1 (2)0
 Asian4 (10)8 (20)
 Other4 (10)3 (7)
Diabetes mellitus, N (%)
 Type 11 (2)3 (8)
 Type 216 (40)20 (50)
Causes of ESKD, N (%)
 Diabetes mellitus15 (40)20 (50)
 PCKD3 (8)4 (10)
 GN10 (26)8 (20)
 Other/unknown10 (26)8 (20)
Medications
 Calcium carbonate, N (%)35 (88)a39 (98)
 Total elemental calcium dose, g, median (IQR, 25%–75%)900 (600–1200)800 (600–1200)
 Sevelemer hydrochloride, N (%)4 (10)2 (5)
 Total daily Renagel dose4000 (800)4267 (2571)
α-Calcidiol, N (%)0 (0)1 (2)
 Calcitriol, N (%)21 (53)12 (30)
 Calcitriol dose per week, μg, mean (IQR, 25%–75%)1.5 (0.75–1.75)1.12 (0.75–1.68)
 Cholecalciferol, N (%)13 (33)12 (30)
 Cholecalciferol dose per day (IU), mean (SD)1169 (373)1066 (463)
Laboratory values
 Phosphate, mmol/L, mean (SD)2.04 (0.61)1.94 (0.50)
 Calcium, mmol/L, mean (SD)2.16 (0.17)2.28 (0.19)
 Albumin, g/L, mean (SD)31.6 (5.5)32.1 (4.6)
 PTH, pmol/L, median (IQR, 25%–75%)34.7 (24.3–48.2)30.4 (18.6–70.2)
 Kt/V, weekly, mean (SD)1.97 (0.46)2.02 (0.35)
 CrCl, ml/min, mean (SD)77.03 (23.51)75.28 (17.18)
  • PCKD, polycystic kidney disesase; IQR, interquartile range; PTH, parathyroid hormone, CrCl, creatinine clearance.

  • a One patient at baseline was taking calcium acetate.